U.S. Navy to Deploy Floating Hospitals with Beckman Coulter Equipment on Board

Our hematology and microbiology systems will be on board U.S. naval ships providing general hospital relief during the COVID-19 outbreak.
U.S. Navy to Deploy Floating Hospitals with Beckman Coulter Equipment on Board

On March 18, President Trump announced that the U.S. Navy will deploy the USNS Comfort and Mercy Naval Floating Hospitals to New York and Los Angeles, respectively. These naval ships will provide general hospital relief, allowing local hospitals to focus their attention on COVID-19 cases. We’re proud to have hematology and microbiology systems on board to alleviate medical needs in those locations.

For more than 16 years, we have supplied the U.S. Navy with the medical equipment needed to support humanitarian relief operations both domestically and globally.

You can read more on the U.S. Department of Defense website.

Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

Get to Know Advantaged Workflows

Get to Know Advantaged Workflows

It takes the right combination of efficiency, accuracy, technology, and clinical expertise to transform a workflow into a unique advantage—and we’re here to help find the right combination for you.
Blood-Based Biomarkers and the Future of Alzheimer’s Disease Diagnostics

Blood-Based Biomarkers and the Future of Alzheimer’s Disease Diagnostics

We sat down with our own Alzheimer’s disease and dementia subject matter expert, Dr. Arindam Ghosh, to learn the potential of blood-based biomarkers to transform the approach to Alzheimer’s disease diagnosis and management.
Exploring the Potential Role of Blood-Based Biomarkers in Identifying and Monitoring Alzheimer's Disease

Exploring the Potential Role of Blood-Based Biomarkers in Identifying and Monitoring Alzheimer's Disease

At the 2024 Clinical Trials in Alzheimer’s Disease (CTAD 2024) conference in Madrid, Spain, discussed the promise of blood-based diagnostic biomarkers.